Results 101 to 110 of about 2,404 (154)

How a major discovery can become a public health failure when used subotptimally: lessons from early nirsevimab implementation

Italian Journal of Pediatrics
Background In this Debate, based on our clinical data from the “pre-nirsevimab” and “first year of nirsevimab implementation” bronchiolitis seasons, we challenge the validity of policy decisions that led to partial immunization coverage of eligible ...
Danilo Buonsenso, Aida Perramon-Malavez, Rosa Morello, Carolina Gentili, Marta Bellorofonte, Antoni Soriano-Arandes   +5 more
doaj   +1 more source

Estimating the Public Health and Economic Impact of Immunisation with Nirsevimab or Maternal Immunisation for the Prevention of RSV-Related Outcomes Over Infants’ First RSV Season in the UK

Infectious Diseases and Therapy
Introduction Respiratory syncytial virus (RSV) poses a significant health burden on infants, particularly during their first RSV season. Immunoprophylactic strategies, such as the administration of nirsevimab, a long-acting monoclonal antibody, have been
Mersha Chetty, Paul Costello, Benjamin Yarnoff, Robert Musci, Mehdi Ghemmouri   +4 more
doaj   +1 more source

Efficacy and safety of a single dose of nirsevimab against respiratory syncytial virus infection in infants: a meta-analysis and time-to-event analysis

Italian Journal of Pediatrics
Respiratory syncytial virus (RSV) is one of the causes of lower respiratory tract infections (LRTIs) and related hospitalizations in neonates and infants.
Mohamed Saad Sayed, Mena Ayman Elgendy, Nada Gamil, Hossam Hassan Abdullah, Alaa Alhwary, Rahma Abdulfattah Ibrahim, Sama Hesham Samir, Nada S. Jibril, Hebatullah Abdulazeem, Mohammed Alsabri   +9 more
doaj   +1 more source

Guideline for Weighing of Infants for Nirsevimab Administration.

Purpose To provide a standardised approach to determine the correct Nirsevimab dose for infants attending a catch-up clinic including mobile vaccination clinics: ensuring accurate dosing while avoiding unnecessary ...
Health Protection Surveillance Centre (HPSC)
core  

Genomic Surveillance and Antigenic Characterization of Respiratory Syncytial Virus (RSV) in Spain During the 2023-2024 Season of Nirsevimab Administration

Respiratory Syncytial Virus (RSV) is a leading cause of respiratory infections in infants and older adults. In Spain, surveillance is supported by the SiVIRA system and the RELECOV genomic sequencing network.
Mas, Vicente, Campoy, Albert, García, María Luz, Alcolea, Sonia, Moreno-Parrado, Laura, Reina, Jordi, Calvo, Cristina, Lepe Jiménez, José Antonio, Iglesias-Caballero, María, Casas, Inmaculada, Pérez, Zulema, Lepe, José Antonio, Casas Flecha, Inmaculada, Antón, Andrés, Perez-Castro, Sonia, Navascués, Ana, Camarero-Serrano, Sara, Costa, José, Cano, Olga, Pozo Sanchez, Francisco, Fernández-González, Ana, Davina-Nunez, Carlos, Gaona, Cristina, Vázquez-Morón, Sonia, Mas-Lloret, Vicente, García-Martínez de Artola, Diego   +25 more
core   +1 more source

Infants needed to immunise with nirsevimab to prevent one RSV hospitalisation, Spain, 2023/24 season

The study was funded by the Institute of Health Carlos III (on its own budget) which, at the institutional level, had no role in the study design, data collection, analysis or interpretation.Using real-life data from Spain between October 2023 and March ...
Nuñez, Olivier, Pastor-Barriuso, Roberto, Monge Corella, Susana, Nirsevimab Effectiveness Study Collaborators, Jarrin Vera, Inmaculada   +4 more
core   +1 more source

Nirsevimab som skydd mot Respiratorisk syncytialvirus (RSV) hos spädbarn : Hur effektivt och säkert är nirsevimab som skydd mot RSV hos friska spädbarn?

Respiratory syncytial virus (RSV) is the leading cause of hospitalization among children and represents a major global health concern. Most RSV cases occur during the RSV season, which is during the cold seasons of the year. The infection often begins as
Awad, Zainab
core   +1 more source

Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in Italy

Objectives: To describe the seasonal respiratory syncytial virus (RSV) burden in Italy considering the current prophylaxis strategy with palivizumab recommended only for high-risk infants (representing only 4.4% of an estimated birth cohort) and to ...
Marcellusi, A, Bozzola, E, Boccalini, S, Baraldi, E, Kieffer, A, Muzii, B, Soudani, S, Orfeo, L, Beuvelet, M, Bini, C, Midulla, F, Bonanni, P, Bozzola E, Boccalini S, Bonanni P, Orfeo L., Marcellusi A, Baraldi E, Kieffer A, Midulla F, Beuvelet M, Muzii B, Bini C, Soudani S   +23 more
core   +1 more source

Correction: Budget Impact of Strategies Involving RSVpreF and Nirsevimab to Protect Infants in Saudi Arabia Against Respiratory Syncytial Virus. [PDF]

Infect Dis Ther
Alharbi AS, Abu-Shraie N, Al Abdulkarim H, Alharbi IH, Averin A, Law AW, Mendes D, Quinn E, Zayed M, Behiry A, Haridy H, Mousa M.   +11 more
europepmc   +1 more source

The Effectiveness of Nirsevimab on Antibiotic Use in Children Using Target Trial Emulation. [PDF]

Clin Infect Dis
Ahmed MM, Joerger T, Wang Z, Li Y, Gerber JS.   +4 more
europepmc   +1 more source